SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-22-001546
Filing Date
2022-05-16
Accepted
2022-05-16 06:04:17
Documents
63
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 20-F aktx-20211231x20f.htm   iXBRL 20-F 2716834
2 EX-2.2 aktx-20211231xex2d2.htm EX-2.2 232248
3 EX-23.1 aktx-20211231xex23d1.htm EX-23.1 2935
4 EX-31.1 aktx-20211231xex31d1.htm EX-31.1 14931
5 EX-31.2 aktx-20211231xex31d2.htm EX-31.2 15085
6 EX-32.1 aktx-20211231xex32d1.htm EX-32.1 9545
7 EX-32.2 aktx-20211231xex32d2.htm EX-32.2 9538
  Complete submission text file 0001410578-22-001546.txt   8724428

Data Files

Seq Description Document Type Size
8 EX-101.SCH aktx-20211231.xsd EX-101.SCH 45942
9 EX-101.CAL aktx-20211231_cal.xml EX-101.CAL 37048
10 EX-101.DEF aktx-20211231_def.xml EX-101.DEF 218766
11 EX-101.LAB aktx-20211231_lab.xml EX-101.LAB 356101
12 EX-101.PRE aktx-20211231_pre.xml EX-101.PRE 323212
57 EXTRACTED XBRL INSTANCE DOCUMENT aktx-20211231x20f_htm.xml XML 1389120
Mailing Address 24 WEST 40TH STREET 8TH FLOOR NEW YORK NY 10018
Business Address 24 WEST 40TH STREET 8TH FLOOR NEW YORK NY 10018 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

IRS No.: 981034922 | State of Incorp.: X0
Type: 20-F | Act: 34 | File No.: 001-36288 | Film No.: 22925181
SIC: 2834 Pharmaceutical Preparations